arrow
Return

HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity

delete2019-12-19
delete24
PRE
AI
P
Pascale Sulser
C
Christina Pickel
J
Julia Günter
T
T.M. Leissing
D
Daniel Crean
C
Christopher J. Schofield
R
Roland H. Wenger
C
Carsten C. Scholz *
DOI:10.1096/fj.201902240Rdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Pharmacologic HIF hydroxylase inhibitors (HIs) are effective for the treatment of anemia in chronic kidney disease patients and may also be beneficial for the treatment of diseases such as chronic inflammation and ischemia-reperfusion injury. The selectivities of many HIs for HIF hydroxylases and possible off-target effects in cellulo are unclear, delaying the translation from preclinical studies to clinical trials. We developed a novel assay that discriminates between the inhibition of HIF-alpha prolyl-4-hydroxylase domain (PHD) enzymes and HIF-alpha asparagine hydroxylase factor inhibiting HIF (FIH). We characterized 15 clinical and preclinical HIs, categorizing them into pan-HIF-alpha hydroxylase (broad spectrum), PHD-selective, and FIH-selective inhibitors, and investigated their effects on HIF-dependent transcriptional regulation, erythropoietin production, and cellular energy metabolism. While energy homeostasis was generally maintained following HI treatment, the pan-HIs led to a stronger increase in pericellular pO(2) than the PHD/FIH-selective HIs. Combined knockdown of FIH and PHD-selective inhibition did not further increase pericellular pO(2). Hence, the additional increase in pericellular pO(2) by pan- over PHD-selective HIs likely reflects HIF hydroxylase independent off-target effects. Overall, these analyses demonstrate that HIs can lead to oxygen redistribution within the cellular microenvironment, which should be considered as a possible contributor to HI effects in the treatment of hypoxia-associated diseases.
Keywords:
anemia
hypoxia
2-oxoglutarate oxygenase inhibitor
prolyl hydroxylase inhibitor
Roxadustat
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

FASEB Journal cover
FASEB Journal
IF:
4.2
Papers:
3.1W
Citations:
4.9W

Organization

U
university of zurich
Scholars:
5.1W
Papers: 4.0W
Citations: 65
U
university college dublin
Scholars:
2.6W
Papers: 2.2W
Citations: 22
Cited Papers

Cited Papers

Lipoproteins of Enterococcus faecalis: bioinformatic identification, expression analysis and relation to virulence
err2011-11-01
err0
PREAI
errFany Reffuveille; Charlène Leneveu; Sylvie Chevalier; Yanick Auffray; Alain Rincé
errShare
errSave
Oxygen sensing by HIF hydroxylases
err2004-05-01
err1.9K
PREAI
errSchofield, CJ; Ratcliffe, PJ
errShare
errSave
Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
err2014-10-31
err307
errOAAI
errEltzschig, Holger K.; Bratton, Donna L.; Colgan, Sean P.
errShare
errSave
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
err2006-03-01
err2.1K
errOAAI
errPapandreou, I; Cairns, RA; Fontana, L; Lim, AL; Denko, NC
errShare
errSave
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
err2016-01-01
err0
errOAAI
errFloriana Morgillo; Carminia Maria Della Corte; Morena Fasano; Fortunato Ciardiello
errShare
errSave
Oxygen-dependent bond formation with FIH regulates the activity of the client protein OTUB1
err2019-09-01
err17
errOAAI
errPickel, Christina; Gunter, Julia; Ruiz-Serrano, Amalia; Spielmann, Patrick; Fabrizio, Jacqueline-Alba; Wolski, Witold; Peet, Daniel J.; Wenger, Roland H.; Scholz, Carsten C.
errShare
errSave
Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype
err2019-02-01
err44
errOAAI
errImeri, Faik; Nolan, Karen A.; Bapst, Andreas M.; Santambrogio, Sara; Abreu-Rodriguez, Irene; Spielmann, Patrick; Pfundstein, Svende; Libertini, Silvana; Crowther, Lisa; Orlando, Ilaria M. C.; Dahl, Sophie L.; Keodara, Anna; Kuo, Willy; Kurtcuoglu, Vartan; Scholz, Carsten C.; Qi, Weihong; Hummler, Edith; Hoogewijs, David; Wenger, Roland H.
errShare
errSave
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
err2002-09-26
err577
errOAAI
errIvan, M; Haberberger, T; Gervasi, DC; Michelson, KS; Günzler, V; Kondo, K; Yang, HF; Sorokina, I; Conaway, RC; Conaway, JW; Kaelin, WG
errShare
errSave
The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases
err2019-07-09
err27
errOAAI
errRoatsch, Martin; Hoffmann, Inga; Abboud, Martine, I; Hancock, Rebecca L.; Tarhonskaya, Hanna; Hsu, Kuo-Feng; Wilkins, Sarah E.; Yeh, Tzu-Lan; Lippl, Kerstin; Serrer, Kerstin; Moneke, Isabelle; Ahrens, Theresa D.; Robaa, Dina; Wenzler, Sandra; Barthes, Nicolas P. F.; Franz, Henriette; Sipp, Wolfgang; Lassmann, Silke; Diederichs, Sven; Schleicher, Erik; Schofield, Christopher J.; Kawamura, Akane; Schuele, Roland; Jung, Manfred
errShare
errSave
researcher View more